Osteoarthritis (OA) is the most prevalent joint disease in humans, often causing disability in affected individuals, especially the elderly. OA is characterized by mechanical joint pain, crepitus and short-term post-immobilization stiffness. OA pain has a variable pathophysiology and, despite the many pharmacological options available, its treatment is often ineffective and has significant side effects. The search for more effective and safer treatments is therefore essential in the field of OA. Among the possible treatments are substances derived from cannabis. Cannabis plants have been used for various purposes by humankind for thousands of years. Its best-known species, Cannabis sativa, has more than a hundred substances called cannabinoids or, more specifically, phytocannabinoids, the most important of which is cannabidiol (CBD). Although many pre-clinical studies indicate the usefulness of phytocannabinoids, clinical evidence for their application is currently scarce. Therefore, this project aims to investigate the effects of a CBD-rich extract of Cannabis sativa on the pain of patients with knee OA, as well as the possible adverse events of this treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
45
Placebo
Group 2: Cannabis sativa extract with CBD (45mg/day).
Federal University of Latin American Integration
Foz do Iguaçu, Paraná, Brazil
Pain levels
Change in pain levels, according to the score in the "pain" domain of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), using the Likert scale to assign a value to the answers obtained from the participants. The pain levels according to the score are 0-8 mild, greater than 8-14 moderate, greater than 14- 20 high.
Time frame: 2 months
Short Form Health Survey (SF-12)
Change in the Short Form Health Survey (SF-12) quality of life scores, according to the "maximal walking" and "activities of daily living" domains, where a score of 0 is the worst quality of life and 100 the best.
Time frame: 2 months
Depression
Changes in levels of depression using the Beck Depression scale. Changes in depression levels using the Beck depression scale. The disease level values range from 0-9 indicating that the individual is not depressed, 10-18 indicating mild to moderate depression, 19-29 indicating moderate to severe depression and 30-63 indicating severe depression.
Time frame: 2 months
Adverse events
presence of adverse events (AE) - proportion of patients with AE in the placebo and intervention groups;
Time frame: 2 months
Serious adverse events
presence of serious adverse events (AEs) - description of the serious AEs that may appear in each group.
Time frame: 2 months
Change in sleep quality
The Pittsburgh scale was used to see if there was any change in the participants' quality of sleep. The scale used classifies sleep quality as follows: * Good 0-4 * Bad -10 * Presence of sleep disturbance greater than 10
Time frame: 2 months
Renal Function Panel
Used as form to identify any renal impairment in pacientes that could result in any need of adjusting the dose or need to leave the study.
Time frame: 2 months
Visual Analogue Scale (VAS)
It is used in the healthcare field to measure the intensity of pain a person feels, usually on a scale from 0 to 10, where 0 means 'no pain' and 10 means 'the worst pain imaginable
Time frame: 2 month
Hepatic Panel
Used to monitor liver function in patients, as pacientes are receiving an oil-based medication that may overload the liver.
Time frame: 2 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.